Structure Therapeutics as an oral GLP-1/amylin play
Morgan Stanley is overweight-rated on Structure Therapeutics (GPCR) due to its oral GLP-1 medicine entering phase 3 and its leadership in developing an oral amylin pill.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.